Security
Perspective Therapeutics, Inc. · CATX
CATXNYSE_AMERICANCommon stockCurrentCIK 728387Updated Oct 9, 2026
Name history
IsoRay, Inc. · through Feb 16, 2023Isoray, Inc. · through Feb 16, 2023CENTURY PARK PICTURES CORP · through Aug 3, 2005
CATX price & chart
Loading TradingView…
AMEX:CATX on TradingView ↗About the company
Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, creating an opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.
In the news
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors ↗
Seeking Alpha
At a glance: stocks gapping up premarket ↗
Perspective Therapeutics: 'Strong Buy' On Bamzireotide Navoxetan Reinforced Data And Phase 3 Plans ↗
Here are the major earnings after the close Monday ↗
SEC disclosures
Perspective Therapeutics, Inc. files 8-K: Material Event ↗
Recent filings
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
SCHEDULE 13D/A - filed by Lantheus Holdings, Inc. regarding Perspective Therapeutics, Inc.
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 266,972,000Source | 341,101,000Source | 97,891,000Source | 64,439,000Source |
| Property, Plant and Equipment, NetUSD | 76,597,000Source | 57,321,000Source | 5,576,000Source | 1,976,000Source |
| GoodwillUSD | — | 0Source | 24,062,000Source | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 362,000Source | 279,000Source | 354,000Source | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 30,629,000Source | 61,580,000Source | 9,238,000Source | 55,890,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 6,000Source | 116,000Source | 1,165,000Source | — |
| Inventory, NetUSD | — | — | — | 1,396,000Source |
| Assets, CurrentUSD | 148,389,000Source | 231,160,000Source | 16,837,000Source | 59,329,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,646,000Source | 4,128,000Source | 1,133,000Source | 435,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,500,000Source | 2,215,000Source | 747,000Source | 512,000Source |
| Other Assets, NoncurrentUSD | 486,000Source | 405,000Source | 487,000Source | 107,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 59,941,000Source | 50,433,000Source | 22,712,000Source | 3,162,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 74,000Source | 70,000Source | 282,000Source | 142,000Source |
| Retained Earnings (Accumulated Deficit)USD | -334,840,000Source | -231,719,000Source | -152,440,000Source | -98,597,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 110,000Source | -51,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 207,031,000Source | 290,668,000Source | 75,179,000Source | 61,277,000Source |
| Additional Paid in Capital, Common StockUSD | 541,687,000Source | 522,368,000Source | 227,337,000Source | 159,732,000Source |
| Liabilities and EquityUSD | 266,972,000Source | 341,101,000Source | 97,891,000Source | 64,439,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 28,679,000Source | 18,230,000Source | 15,664,000Source | 2,266,000Source |
| Operating Lease, Liability, CurrentUSD | 623,000Source | 957,000Source | 46,000Source | 268,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,005,000Source | 1,428,000Source | 780,000Source | 256,000Source |
| Deferred Income Tax Liabilities, NetUSD | 1,702,000Source | 2,495,000Source | 4,592,000Source | — |
| Other Liabilities, NoncurrentUSD | 386,000Source | 55,000Source | — | — |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 144,700,000Source | 226,900,000Source | — | — |
| Deferred Tax Liabilities, NetUSD | 1,702,000Source | 2,495,000Source | 4,592,000Source | — |
| Long-term DebtUSD | 1,625,000Source | 1,677,000Source | 1,725,000Source | — |
| Short-term InvestmentsUSD | 114,108,000Source | 165,336,000Source | 0Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 8,966,000Source | 5,387,000Source | 3,738,000Source | 1,087,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -110,000Source | -1,049,000Source | 426,000Source | -405,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | -359,000Source | 2,673,000Source |
| Deferred Income Tax Expense (Benefit)USD | -793,000Source | -2,097,000Source | -2,651,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -82,484,000Source | -18,294,000Source | -36,913,000Source | -7,710,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 41,228,000Source | -218,931,000Source | 24,373,000Source | -284,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 12,749,000Source | 54,414,000Source | 1,072,000Source | 266,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 10,305,000Source | 289,385,000Source | 785,000Source | 56,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -30,951,000Source | 52,160,000Source | -11,755,000Source | -7,938,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | 84,000Source | — |
| Income Taxes Paid, NetUSD | 30,000Source | — | — | — |
| Additional Financial Items | ||||
| AmortizationUSD | — | — | 40,000Source | 41,000Source |
| Share-based Payment Arrangement, ExpenseUSD | 8,966,000Source | 5,221,000Source | 3,143,000Source | 1,087,000Source |
| Amortization of Intangible AssetsUSD | 7,000Source | 7,000Source | 7,000Source | 41,000Source |
| Asset Retirement Obligation, Accretion ExpenseUSD | — | — | 35,000Source | 32,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 144,700,000Source | 226,900,000Source | — | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | 0Source | 0Source | — | — |
| DepreciationUSD | — | — | 946,000Source | 248,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -250,000Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | 0Source | -27,000Source | 0Source | 0Source |
| Gain (Loss) on Disposition of BusinessUSD | 0Source | -59,000Source | -4,170,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | 0Source | -27,000Source | -22,000Source | 0Source |
| General and Administrative ExpenseUSD | 30,233,000Source | 26,613,000Source | 21,064,000Source | 6,621,000Source |
| GoodwillUSD | — | 0Source | 24,062,000Source | — |
| Goodwill, Impairment LossUSD | 0Source | 24,062,000Source | — | — |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | 10,000,000Source | 0Source | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | -2,000Source | -8,000Source | -17,000Source | — |
| Income Tax Expense (Benefit)USD | -793,000Source | -2,097,000Source | -2,651,000Source | 0Source |
| Inventory Write-downUSD | — | — | 298,000Source | — |
| Investment Income, InterestUSD | 8,114,000Source | 10,515,000Source | 934,000Source | 119,000Source |
| Net Income (Loss) Attributable to ParentUSD | -103,121,000Source | -79,279,000Source | -46,508,000Source | -7,272,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -7,272,000Source |
| Nonoperating Income (Expense)USD | 9,136,000Source | 10,459,000Source | 835,000Source | 119,000Source |
| Operating ExpensesUSD | 114,448,000Source | 92,340,000Source | 42,375,000Source | 12,007,000Source |
| Operating Lease, ExpenseUSD | 100,000Source | 800,000Source | 97,000Source | 312,000Source |
| Proceeds from Issuance of Common StockUSD | — | 275,807,000Source | 364,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 371,000Source | 1,253,000Source | 554,000Source | 56,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 1,434,000Source | 10,795,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of RevenueUSD | — | — | — | 6,179,000Source |
| Operating Income (Loss)USD | -113,564,000Source | -90,886,000Source | -40,941,000Source | -7,391,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -104,428,000Source | -80,427,000Source | -40,106,000Source | — |
| Income Tax Expense (Benefit)USD | -793,000Source | -2,097,000Source | -2,651,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -103,121,000Source | -79,279,000Source | -46,508,000Source | -7,272,000Source |
| Earnings Per Share, BasicUSD per share | -1.4Source | -1.23Source | -0.17Source | -0.05Source |
| Earnings Per Share, DilutedUSD per share | -1.4Source | -1.23Source | — | — |
| Total Revenue | — | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 73,813,000Source | 64,425,000Source | 267,643,000Source | 141,987,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 73,813,000Source | 64,425,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 7,000Source | 7,000Source | 7,000Source | 41,000Source |
| Current Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 3,251,000Source | 2,306,000Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -250,000Source | — | — | — |
| General and Administrative ExpenseUSD | 30,233,000Source | 26,613,000Source | 21,064,000Source | 6,621,000Source |
| Goodwill, Impairment LossUSD | 0Source | 24,062,000Source | — | — |
| Gross ProfitUSD | — | — | 1,434,000Source | 4,616,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -104,428,000Source | -79,989,000Source | — | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -1.41Source | -1.22Source | -0.14Source | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -1.41Source | -1.22Source | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | -2,000Source | -8,000Source | -17,000Source | — |
| Interest ExpenseUSD | — | — | 84,000Source | — |
| Investment Income, InterestUSD | 8,114,000Source | 10,515,000Source | 934,000Source | 119,000Source |
| Marketing and Advertising ExpenseUSD | — | — | — | 129,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -7,272,000Source |
| Nonoperating Income (Expense)USD | 9,136,000Source | 10,459,000Source | 835,000Source | 119,000Source |
| Operating ExpensesUSD | 114,448,000Source | 92,340,000Source | 42,375,000Source | 12,007,000Source |
| Operating Lease, ExpenseUSD | 100,000Source | 800,000Source | 97,000Source | 312,000Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | — | 0Source |
| Research and Development ExpenseUSD | 84,215,000Source | 41,638,000Source | 21,311,000Source | 2,582,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 1,434,000Source | 10,795,000Source |
| Selling and Marketing ExpenseUSD | — | — | — | 2,804,000Source |
Filing attachments
catx-ex99_1.htm · 8-K · 2026-10-08
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors SEATTLE, Oct. 08, 2026 -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the U.S. Food and Drug Administration …
Read attachment ↗catx-ex99_1.htm · 8-K · 2026-10-01
Next-Generation Radiopharmaceuticals Redefining Targeted Oncology Designed to be the Most Potent Payload in Targeted Oncology Three Independent Clinical-Stage Programs, Each Against a Distinct Target with Data in 2026 Deep Leadership Across Radiopharmaceutical and Drug Development The Perspective Story in Four Parts Radiopharmaceutical Therapy: A Category Still Early in Its Adoption Curve Targeted Delivery of Payloads is Transforming Oncology Therapy $45 Billion+ Addressable Market, Alre…
Read attachment ↗catx-ex99_1.htm · 8-K · 2026-09-14
EX-99.1 2 catx-ex99_1.htm EX-99.1 EX-99.1 Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors SEATTLE, September 14, 2026 -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announce…
Read attachment ↗catx-ex99_1.htm · 8-K · 2026-09-08
EX-99.1 2 catx-ex99_1.htm EX-99.1 Next-Generation Radiopharmaceuticals Redefining Targeted Oncology Designed to be the Most Potent Payload in Targeted Oncology Three Independent Clinical-Stage Programs, Each Against a Distinct Target with Data in 2026 Deep Leadership Across Radiopharmaceutical and Drug Development The Perspective Story in Four Parts Radiopharmaceutical Therapy: A Category Still Early in Its Adoption Curve Radiopharmaceutical Therapy Is the Next Generation of Targeted …
Read attachment ↗catx-ex99_1.htm · 8-K · 2026-08-10
EX-99.1 2 catx-ex99_1.htm EX-99.1 EX-99.1 Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results • Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 subject to regulatory feedback; sufficient isotope access and manufacturing capacity • VMT-α-NET study update accepted for oral presentation at ESMO 2026 • VMT01 melanoma …
Read attachment ↗catx-ex99_2.htm · 8-K · 2026-08-10
EX-99.2 3 catx-ex99_2.htm EX-99.2 Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals Engineering the Alpha Advantage in Targeted Oncology Unlocking New Treatment Options Across Solid Tumors: Optimizing the Entire System Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals Optimizing Structural Chemistry: Choosing the Right Isotope Not All ²¹²Pb Programs Are Created Equal Advancing a Theranostic Approach: Solid Tumors are an Attractive Market for …
Read attachment ↗